MARKET

DMAC

DMAC

Diamedica Therapeutics Inc
NASDAQ
1.470
+0.030
+2.08%
Closed 16:00 01/27 EST
OPEN
1.480
PREV CLOSE
1.440
HIGH
1.488
LOW
1.455
VOLUME
8.87K
TURNOVER
6.36K
52 WEEK HIGH
3.225
52 WEEK LOW
1.120
MARKET CAP
38.87M
P/E (TTM)
-2.9530
1D
5D
1M
3M
1Y
5Y
FDA clinical holds pick up amid race for risky, innovative medicines – WSJ
Seeking Alpha · 01/10 14:45
Insider Buying: The DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Independent Director Just Bought 38% More Shares
Whilst it may not be a huge deal, we thought it was good to see that the DiaMedica Therapeutics Inc. ( NASDAQ:DMAC...
Simply Wall St. · 12/04/2022 12:04
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
Benzinga · 12/02/2022 13:43
DiaMedica Therapeutics GAAP EPS of -$0.12 beats by $0.03
Seekingalpha · 11/09/2022 22:22
DiaMedica Therapeutics Q3 EPS $(0.12) Up From $(0.18) YoY
Benzinga · 11/09/2022 22:09
DiaMedica Therapeutics to Attend the 13th Annual Craig-Hallum Alpha Select Conference November 17, 2022
MINNEAPOLIS, November 07, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and...
Business Wire · 11/07/2022 13:32
DiaMedica Therapeutics to Present at Credit Suisse 31st Annual Healthcare Conference
MINNEAPOLIS, October 31, 2022--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls, its President and ...
Business Wire · 10/31/2022 12:32
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Benzinga · 10/28/2022 08:57
More
About DMAC
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for neurological and kidney diseases, such as acute ischemic stroke (AIS) and chronic kidney disease (CKD). The Company's lead product DM199 mimics the behavior of naturally occurring human kallikrein-1 (KLK1) proteins to preserve and restore circulation to stroke-damaged tissue and improve overall kidney function. KLK1 is a serine protease, or protein, produced primarily in the kidneys, pancreas and salivary glands. DM199 therapy has the potential to improve circulation and overall function of critical systems, as well as reduce inflammation and oxidative stress. The Company also has other product pipelines for IgA Nephropathy and African Americans with CKD.

Webull offers kinds of DiaMedica Therapeutics Inc stock information, including NASDAQ:DMAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DMAC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DMAC stock methods without spending real money on the virtual paper trading platform.